Filing Flows › Health Care › Envoy Medical (COCH)
Envoy Medical (COCH) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Envoy Medical (COCH) Q3 2026 earnings results →
Q3 2026 Revenue up 57% year over year to $66K
Envoy Medical made $66K in Q3 2026 (+57% Y/Y). Operating margin n/m, net loss $3.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $66K in Q3 2026, up 57% year over year and up 29% from the previous quarter.
Operating costs exceeded revenue by $5.5M, an operating margin of -8389.4%. Total costs grew 6% against revenue growth of 57%. The fastest-growing cost line was Cost of revenue (+20%). The quarter ended with a net loss of $3.9M, narrower than the previous quarter's $6.0M loss. Non-operating items added $1.6M, -41% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$5.0M. Non-cash charges added back $75K of depreciation and $307K of share-based compensation. Working capital and other items used $1.5M. Capital expenditures of $27K exceeded it, leaving free cash flow of −$5.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $66K | +57% | n/m | −$3.9M | −$5.0M |
| Q2 2026 | 10-Q | Aug 10, 2026 | $51K | -35% | n/m | −$6.0M | −$5.5M |
| Q1 2026 | 10-Q | May 11, 2026 | $39K | -15% | n/m | −$4.4M | −$6.1M |
| Q4 2025 | 10-K | Mar 23, 2026 | $75K | +79% | n/m | −$6.6M | −$5.7M |
| Q3 2025 | 10-Q | Nov 10, 2025 | $42K | -25% | n/m | −$6.5M | −$4.3M |
| Q2 2025 | 10-Q | Jul 31, 2025 | $78K | +15% | n/m | −$5.7M | −$4.5M |
| Q1 2025 | 10-Q | May 1, 2025 | $46K | -22% | n/m | −$5.0M | −$3.7M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Envoy Medical
Unless otherwise noted or the context otherwise requires, all references in this section to “Envoy Medical,” “we,” “us” or “our” refer to Envoy Medical, Inc. following the Business Combination, other than certain historical information which refers to the business of Legacy Envoy prior to the consummation of the Business Combination. We are a hearing health company focused on providing innovative medical technologies across the hearing loss spectrum. Our technologies are designed to shift the paradigm within the hearing industry and bring both providers and patients the hearing devices they desire. We are dedicated to pushing beyond the status quo to provide patients with improved access, usability, independence, and quality of life. We believe leveraging the ear’s natural anatomy, rather than external or sub-dermal artificial microphone, is the ideal way for people to hear.
In its own words, from its 10-K, filed Mar 23, 2026.
Envoy Medical against its Orthopedic, Prosthetic & Surgical Appliances & Supplies peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +57% against the peers' median +10%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| COCH Envoy Medical | Q3 2026 | $66K | +57% | n/m |
| ISRG Intuitive Surgical | Q3 2026 | $3.0B | +22% | 19.4% |
| ZBH Zimmer Biomet Holdings | Q3 2026 | $2.1B | +3% | 14.9% |
| EW Edwards Lifesciences | Q3 2026 | $1.7B | +10% | 17.4% |
| STE Steris | Q2 FY27 | $1.6B | +9% | 18.5% |
| ALGN Align Technology | Q3 2026 | $1.0B | +2% | 16.7% |
| ENOV Enovis | Q3 2026 | $559M | +2% | 0.6% |
| MSA MSA Safety | Q3 2026 | $536M | +14% | 16.4% |
| CDRE Cadre Holdings | Q3 2026 | $203M | +30% | 14.0% |
Source: Envoy Medical 10-Q on SEC EDGAR · CIK 1840877 · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Guidance and outlook
13F: who owns COCH and who is buying
More on COCH
- How Envoy Medical makes money: revenue by segment
- Envoy Medical next earnings date and what analysts expect
- Envoy Medical stock forecast, price target and fair value
- Who owns Envoy Medical stock: holders, funds and Congress trades
- Envoy Medical guidance and outlook
- Envoy Medical recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results